Lokon Pharma

Next generation cancer immunotherapeutics

Our solution

Clinical trials

LOKON001

Phase I/II study for pancreatic cancer

‍

‍

‍

Ongoing

LOKON002

Phase I/II study for patients with pancreatic-, biliary-, ovarian-, and colorectal cancer.

‍

‍

Completed

LOKON003

Phase I/II study for patients with malignant melanoma.

‍

‍

‍

Completed

Pipeline

The LOAd family includes a range of novel tumor microenvironment (TME) gene engineering vectors with different immunostimulatory genes that are currently being evaluated for mechanisms-of-action (MOA) and proof-of-concept (POC).

See our pipeline

For patients

If you live in the US and have pancreatic cancer or melanoma, you may be eligible for inclusion in our clinical trials LOKON001 or LOKON003. If you live in Sweden and have pancreatic cancer, melanoma, or ovarian cancer, you may be eligible for inclusion in our clinical trials LOKON002 or LOKON003. If you are interested to participate as a study patient in our trials, please, discuss with your treating physician.

About Lokon

Lokon Pharma is a Swedish biotech company in the forefront of developing tumor microenvironment (TME) gene engineering vectors for cancer. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Press releases

News

Results from first pancreatic cancer trial using immunostimulatory gene therapy is published in Lancet Oncology

January 12, 2022

Lokon Pharma Initiates a Collaboration with Affibody to Develop Novel Cancer Therapeutics

August 28, 2020

Lokon Pharma Expands Collaboration with Roche Evaluating LOAd703 Immunostimulatory Gene Cancer Therapy in Combination with Tecentriq® (atezolizumab) into Colorectal Cancer

Lokon Pharma Announces Collaboration to Combine LOAd703 Oncolytic Virotherapy with Checkpoint Blockade in Pancreatic Cancer and Melanoma

January 19, 2017

First Patient Treated by a Novel Oncolytic Virus Armed with Immune Stimulators

September 13, 2024

Gustav Ullenhag, principal investigator of the LOKON003 trial presented the study at ESMO in Barcelona. In this study, LOAd703 TME gene engineering was used for patients with malignant melanoma in combination with PD-1/PD-L1 blockade.

September 13, 2024

Angelica Loskog, the CEO/CSO at Lokon presented data from the LOKON002 trial at ESMO. In this study, LOAd703 TME gene engineering was combined with chemotherapy in solid malignancies.

August 31, 2023

Sara Häggblad, Head of CMC and Titti Björnström, Head of QC/QA from Lokon Pharma will attend the viral vector process development summit on the 30-31th of August. Lokon Pharma will also have a presentation on “Setting out the right criteria for CDMO partners, and how to overcome capacity and availability for viral vector production for speed-to-patient”.

Media

Malou efter 10

Bengt fick aggressiv cancer - hade ett år kvar att leva

Barncancerfonden

Immunterapi på 100 sekunder

Malou efter 10

Forskarna om cancervaccinet: ”Behövs pengar”

Uppsala universitet

Immunterapi är ett nytt sätt att bekämpa cancer.